Life Science News

algae based omega 3 supplements

Solarvest Files Annual Financial Statements and MD&A


Solarvest BioEnergy Inc.

TheNewswire - November 19 th 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS) is pleased to announce that its audited financial statements for the year ended July 31, 2021, related management discussion and analysis and associated officer's certifications (collectively, the "Annual Filings") have been filed and are now available on .

Gerri Greenham, CEO, said "we are pleased with the progress we have made since July 2020 to the financial year end of 2021. We have achieved several key milestones in a relatively short period of time."  The following are some highlights:

Organic Omega-3 Update

This past year Solarvest has made significant strides toward commercialization of its first line of organic Omega-3 DHA products. As a result of our R&D programs, we are now able to expand into production, licensing, sales and marketing.

Our efforts were focused on product development this past year.  We have created three new product formulations resulting in 6 new retail packages, based on our proprietary foundation of organic certified Omega-3.  This product line will substantially increase our attractiveness on e-commerce platforms and to white label customers.

The first completed product is a presentation of three 60ml shots — Stamina, Recover and Vision . The functional shots market is expected to grow at 16% per year to $1.4 billion in 2027 according to Research and Markets *. The Company's convenient 60ml shots are formulated to supplement the essential daily Omega-3 requirement with added organic ingredients.  For example, Stamina includes ingredients that are known to dilate blood vessels, an effect that may lower blood pressure and increase exercise time to task failure. Recover includes ingredients that, in addition to Omega-3, are known to reduce inflammation.  The market goes beyond the professional athlete seeking a competitive boost to anyone wishing to enhance their workout and manage the resulting inflammation.  The Vision customer is expected to be anyone that experiences blue light toxicity and screen fatigue, common in our screen heavy work environments.

The second developed product is a line of four organic powder blends. The flagship in this range is a high dose Omega-3 powder providing 450mg of natural triglyceride DHA.  The remaining powders are based on shot formulations with similar active ingredients and flavours.

The third completed product is the enhancement of our dried fruit gummy product for children.  The Company employed a mother-oriented market research company to introduce and sample our Zing fruit gummy.  We had very positive feedback and almost unanimous support for the formulation, tested ingredients and clean label.  Taking this input into consideration, the Company decided to implement tooling for a more attractive shape while increasing the size of the gummy.  The result is an attractive fruit section shape and a fruitier flavour. The Company has produced the Fruit Slice gummy and is in the process of producing inventory to be shipped to China for a launch with our distributor OrgHive.

Animal Health

The Company entered into an arrangement with the Scoular Company to explore opportunities in the animal health industry.  Omega oils are being used in the aquaculture industry through the incorporation of fish oil and fishmeal into commercial fish feed. Scoular and Solarvest are exploring the possibilities of using Solarvest's algae technology with Scoular's ingredient expertise to produce an omega oil that could compete with the wild catch harvested for fish oil and meal.

Initial fermentation trials have determined the suitability of the Scoular by-product as a media component.  The next steps are to optimize the production methodology and assess final product costing.

Protein Expression

Our protein expression program in algae has also made good progress with the short-term goal being to modify the algae strain to product targeted cannabinoid proteins.

The algae protein program was financed through a relationship with a pharma company interested in active pure cannabinoid proteins.  We entered into a share exchange program with the intent of using the funds to further Solarvest activities and commence a cannabinoid expression research program.  The collaboration did not deliver all the funds the partners had expected as the Company suffered a loss on the sale of common shares it received in the share exchange, as we report in the financials with the loss of $1,297,877 on the sale of their securities. We will continue discussions with our partner as we realize the commercial benefits from a successful result to our partner and others in the pharma cannabinoid industry.

For the fiscal year ended July 31 2021 t he Company incurred a net loss of $3,460,003 for the year ended July 31, 2021 compared to $1,541,412 for the prior year.  At July 31, 2021, the Company had $1,388,244 (July 31, 2020 - $ 547,471) in cash. Working capital at July 31, 2021 was $ 587,732 (July 31, 2020 working capital deficiency- $ 226,513). The Company completed a successful financing of $2,297,286 during the year which resulted in the increase in professional costs from $340,882 to $587,995 for 2021.  Many of the investors from this placement were individual, qualified investors, so although the Company saved on financing fees, legal costs did increase.

"We look forward to the coming year as we begin to move toward a growth oriented company," said Gerri Greenham, CEO.

This news release should be read in conjunction with the Annual Filings. The Annual Filings have been reviewed by both the audit committee and the board of directors.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The Company has successfully developed, patented and produced the world's only plant-based organic certified Omega-3 to satisfy the substantial demand for this essential nutrient.  The Company has also initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Gerri Greenham, CEO

Tel.: (647) 204-4095


Forward-Looking Statement

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


Copyright (c) 2021 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)

Aptose Reports Results for the Fourth Quarter and Full Year 2022

─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─

─ RAS Mutated AML Clinically Sensitive to Tuspetinib ─

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Debenture Financing

Sirona Biochem Announces Debenture Financing

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the " Convertible Debentures "). The Company is offering Convertible Debentures units (the " Debenture Units ") at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $1,500,000 (the " Offering ").

Each Debenture Unit will have a face value of (the " Face Value ") of $1,120, consisting of $1,000 in principal (the " Principal ") and $120 in prepaid interest (the " Prepaid Interest "). The Principal of the Debenture Units will accrue interest at a rate of 12% per annum, which accrued interest (" Accrued Interest ") will be paid semi-annually, in arrears. The Company will pay the Prepaid Interest and Accrued Interest in cash or, subject to TSX Venture Exchange (" TSXV ") acceptance, may elect to satisfy payment in kind by issuing Shares (" Interest Shares "). In the event of payment in kind, the number of Interest Shares due will be calculated using a conversion price (the " Interest Conversion Price ") equal to, subject to acceptance by the TSXV, the maximum Discounted Market Price (as defined in TSXV policies) on the applicable payment due date.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AbbVie Advances Upadacitinib to Phase 3 Clinical Trials in Systemic Lupus Erythematosus

  • Results of the M19-130 (SLEek) Phase 2 trial of upadacitinib given alone or as a combination therapy (ABBV-599) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in patients with moderately to severely active SLE 1 , 2
  • No new safety signals were identified with upadacitinib, and a similar safety profile was observed for the combination therapy (ABBV-599) as for treatment with upadacitinib alone 2, 3 , 4 , 5 , 6 , 7
  • SLE is a complex autoimmune disorder in which the body's immune system attacks healthy tissue of the musculoskeletal system, skin, kidneys, lungs and other critical organs, leading to symptoms such as fatigue, joint pain and impaired function. 8 , 9

ABBVie (NYSE: ABBV) today announced topline results from a Phase 2 study of upadacitinib (RINVOQ ® 30 mg) given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib, 60 mg), once daily in patients with moderately to severely active systemic lupus erythematosus (SLE). 1 The SLEek study met the primary endpoint of SLE Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the upadacitinib 30 mg group. 1,2 Based on the results, ABBVie is advancing its clinical program of upadacitinib in SLE to Phase 3.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Risankizumab Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative Colitis

  • A significantly higher proportion of patients with moderately to severely active ulcerative colitis treated with risankizumab achieved the primary endpoint of clinical remission a (per Adapted Mayo Score) compared to placebo at week 12 in the Phase 3 INSPIRE induction study
  • All secondary endpoints, including clinical, endoscopic and histologic outcomes, were met
  • Safety results in this study were consistent with the known safety profile of risankizumab, with no new safety risks observed 1
  • Building on AbbVie's growing gastroenterology portfolio, risankizumab is an IL-23 inhibitor being evaluated as a treatment for adults with moderate to severe ulcerative colitis and approved for Crohn's disease, psoriatic arthritis, and psoriasis 1

ABBVie (NYSE: ABBV) today announced positive top-line results from INSPIRE, a Phase 3 induction study, showing risankizumab (SKYRIZI ® ,1200 mg intravenous [IV], at weeks 0, 4 and 8) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 12, as well as all secondary endpoints in adult patients with moderately to severely active ulcerative colitis. 1 In the study, 20.3% of patients receiving risankizumab achieved clinical remission compared to 6.2% of patients receiving placebo (p

"Our commitment to people living with gastroenterological conditions continues to grow," said Roopal Thakkar , M.D., senior vice president, development, regulatory affairs and chief medical officer, AbbVie. "These encouraging results help support the potential risankizumab has to improve clinical, endoscopic and histologic outcomes in patients with ulcerative colitis."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities

Funding Will Reach Under-Resourced Communities Impacted by the HIV Epidemic as Part of Gilead's Zeroing In™: Ending the HIV Epidemic Grant Program –

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother's Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative. These grants are part of Gilead's ongoing Zeroing In™ program to help end the HIV epidemic by supporting organizations working to improve the overall health and wellness of communities most impacted by the HIV epidemic.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AbbVie Provides Regulatory Update on ABBV-951 New Drug Application

ABBVie (NYSE: ABBV) today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for ABBV-951 (foscarbidopafoslevodopa) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

In its letter, the FDA requested additional information about the device (pump) as part of the NDA review. The CRL does not request that AbbVie conduct additional efficacy and safety trials related to the drug. AbbVie plans to resubmit the NDA as soon as possible.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News